Food In Canada

A boost in funding has gone to scientists developing animal vaccines

Food in Canada   

Food Safety Research & Development Meat &Poultry Genome Canada

Vaccine and Infectious Disease Organization-International Vaccine Centre at the University of Saskatchewan received almost $3 M from Genome Canada to develop vaccines against two diseases

Saskatoon, Sask. – Scientists who are working on developing vaccines against diseases that affect cattle received a funding boost for their work.

Genome Canada gave $2.9 million to the Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) at the University of Saskatchewan.

CowwCalfFreeDigital350x233The scientists are working on vaccines against two diseases that attack the lungs and intestinal tract of cattle.

Bovine tuberculosis affects the lungs of cattle and bison, and wild species such as deer and elk. It can, in some cases, be transmitted to humans.


While more prevalent in the developing world where it causes annual losses of about $3 billion,  says VIDO-InterVac, managing the disease also carries a multi-million-dollar price tag in Canada.

Johne’s disease, caused by a related species of bacteria, results in chronic inflammation of the intestinal tract in cattle. It is a particular problem for dairy herds, causing the animals to sicken and sometimes die.

VIDO-InterVac researchers and their collaborators in Canada and Ireland aim to deliver two new vaccines for these costly mycobacterial diseases. The funding, awarded through Genome Canada’s Genomics and Feeding the Future program, is part of a $7.4 million project over four years.

The team, which includes collaborators at the University of British Columbia and the Agri-Food and Biosciences Institute in Northern Ireland, will use a genomics-based approach called “reverse vaccinology” to identify disease proteins that the cattle immune system will recognize as foreign and react to, explains VIDO-InterVac.

Identification of these proteins is the first step in developing novel vaccines. The project will use VIDO-InterVac’s state-of-the-art containment level 3 facility.

“We have the only facility in Canada with the capacity to conduct vaccine development and testing of this magnitude.” says Andrew Potter, director at VIDO-InterVac.

“Our team will take full advantage of VIDO-InterVac’s containment infrastructure to develop vaccines that will not only improve the health of cattle, but will also enhance Canada’s reputation as a major agri-food producer.”

Print this page


Stories continue below